Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Test Trials: EU Screening Plan Envisions Proxy Endpoint Recognition

This article was originally published in The Gray Sheet

Executive Summary

The European Commission is considering adding further diagnostic cancer screens to the testing it supports in a recently announced call for member states to establish early detection programs

You may also be interested in...



Routine Mammography Not Vital For Women In Their 40’s – NEJM Study

The risks of routine mammography screening for breast cancer detection among women ages 40-49 may outweigh the potential benefits, according to a study in the April 24 New England Journal of Medicine.

USPSTF Drops Opposition To Prostate Screening, Remains Skeptical

The U.S. Preventive Services Task Force will no longer recommend against routine prostate cancer screening, but cautions that the benefits have not been fully demonstrated

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel